HomeCompareSCLN vs JEPQ

SCLN vs JEPQ: Dividend Comparison 2026

SCLN yields 17.94% · JEPQ yields 11.47%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SCLN wins by $18.5K in total portfolio value
10 years
SCLN
SCLN
● Live price
17.94%
Share price
$11.15
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$64.3K
Annual income
$5,372.32
Full SCLN calculator →
JEPQ
JPMorgan Nasdaq Equity Premium Income ETF
● Live price
11.47%
Share price
$53.77
Annual div
$6.16
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$45.8K
Annual income
$2,269.18
Full JEPQ calculator →

Portfolio growth — SCLN vs JEPQ

📍 SCLN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSCLNJEPQ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SCLN + JEPQ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SCLN pays
JEPQ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SCLN
Annual income on $10K today (after 15% tax)
$1,524.66/yr
After 10yr DRIP, annual income (after tax)
$4,566.47/yr
JEPQ
Annual income on $10K today (after 15% tax)
$974.55/yr
After 10yr DRIP, annual income (after tax)
$1,928.80/yr
At 15% tax rate, SCLN beats the other by $2,637.67/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SCLN + JEPQ for your $10,000?

SCLN: 50%JEPQ: 50%
100% JEPQ50/50100% SCLN
Portfolio after 10yr
$55.0K
Annual income
$3,820.75/yr
Blended yield
6.94%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SCLN buys
0
JEPQ buys
0
No recent congressional trades found for SCLN or JEPQ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSCLNJEPQ
Forward yield17.94%11.47%
Annual dividend / share$2.00$6.16
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$64.3K$45.8K
Annual income after 10y$5,372.32$2,269.18
Total dividends collected$34.5K$17.1K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: SCLN vs JEPQ ($10,000, DRIP)

YearSCLN PortfolioSCLN Income/yrJEPQ PortfolioJEPQ Income/yrGap
1← crossover$12,494$1,793.72$11,967$1,146.53+$527.00SCLN
2$15,463$2,094.42$14,216$1,268.02+$1.2KSCLN
3$18,968$2,422.55$16,774$1,392.20+$2.2KSCLN
4$23,073$2,777.26$19,667$1,518.21+$3.4KSCLN
5$27,845$3,157.31$22,925$1,645.21+$4.9KSCLN
6$33,355$3,561.10$26,578$1,772.40+$6.8KSCLN
7$39,677$3,986.73$30,656$1,899.04+$9.0KSCLN
8$46,886$4,432.07$35,194$2,024.45+$11.7KSCLN
9$55,063$4,894.76$40,228$2,148.01+$14.8KSCLN
10$64,290$5,372.32$45,796$2,269.18+$18.5KSCLN

SCLN vs JEPQ: Complete Analysis 2026

SCLNStock

SciClone Pharmaceuticals, Inc. is a global biopharmaceutical company. The Company acquires, develops, and commercializes drugs for treating chronic and life-threatening diseases such as cancer, hepatitis B, hepatitis C, cystic fibrosis, and immune system disorders.

Full SCLN Calculator →

JEPQETF

The fund seeks to achieve this objective by (1) creating an actively managed portfolio of equity securities comprised significantly of those included in the fund’s primary benchmark, the Nasdaq-100 Index (the Benchmark), and (2) through equity-linked notes (ELNs), selling call options with exposure to the Benchmark. It is non-diversified.

Full JEPQ Calculator →
📬

Get this SCLN vs JEPQ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SCLN vs SCHDSCLN vs JEPISCLN vs OSCLN vs KOSCLN vs MAINSCLN vs XYLDSCLN vs QYLDSCLN vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.